drugset / Trial / NCT03707899

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

NCT03707899

Phase 1 Completed 49 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers.

Timeline

Start
2018-12-13
Primary completion
2019-02-18
Completion
2019-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Telmisartan Other / unclassified 80 mg